Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
2 hedge funds and large institutions have $6.76K invested in Protagenic Therapeutics Warrant in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
249% more capital invested
Capital invested by funds: $1.94K → $6.76K (+$4.82K)
0% more ownership
Funds ownership: 4.68% → 4.68% (+0%)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
New York
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $5.74K | – | – | – |
|
|
GS
2
GTS Securities
New York
| $1.02K | +$4 | +200 | +0.8% |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$1 | -100 | Closed |
|
PTIXW Hedge Fund Activity: Q1 2024 in Review
2 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q1 2024, worth a combined $6.76K — up 249% from $1.94K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PTIXW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was GTS Securities, adding an estimated $4. The largest seller was UBS Group, exiting entirely with an estimated $1 sold.
- 2 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q1 2024, down from 3 in Q4 2023.
- Funds reported $6.76K of Protagenic Therapeutics Warrant stock for Q1 2024, up 249% quarter-over-quarter.
- 0 funds opened new Protagenic Therapeutics Warrant positions in Q1 2024 and 1 closed out, a net change of -1 holder.
- The largest Protagenic Therapeutics Warrant buyer in Q1 2024 was GTS Securities, an estimated $4 added.
- The largest Protagenic Therapeutics Warrant seller in Q1 2024 was UBS Group, an estimated $1 sold.
Based on aggregated 13F filings for Q1 2024.